Scinai Immunotherapeutics Ltd

Research Scinai Immunotherapeutics Ltd (SCNI) on Bullrun: market cap USD 951.05K. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerSCNI
• ExchangeNASDAQ
• CountryIsrael
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 951.05K
• Financial periodFY2025
• RevenueUSD 1.31M
• Revenue growth99.2%
• Net income-USD 8.31M
• Free cash flow-USD 6.06M
• Gross margin-202.3%

Valuation Snapshot

latest market cap is USD 951.05K.

About Scinai Immunotherapeutics Ltd

Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis.

Frequently asked questions

What is Scinai Immunotherapeutics Ltd's market cap?

Scinai Immunotherapeutics Ltd's market capitalization is USD 951.05K.

What does Scinai Immunotherapeutics Ltd do?

Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally.